Ferritin Dynamics in Cancer Prognostics

Ferritin, the principal intracellular iron storage protein, has emerged as a multifaceted regulator of cancer progression and patient outcome. Its two subunits—the heavy chain (FTH1) and light chain (FTL)—operate in concert to modulate iron homoeostasis, oxidative stress and cell death pathways such as ferroptosis. Aberrant ferritin expression or localisation in tumours influences processes ranging from DNA damage repair to immune evasion. Elevated serum ferritin often reflects both iron overload and inflammatory states, and correlates with poorer survival across a variety of malignancies. Within the tumour microenvironment, differential expression of FTH1 and FTL in cancer cells and associated immune cells shapes the balance between proliferation, metastasis and therapy resistance. Subcellular partitioning of ferritin, notably nuclear versus cytoplasmic heavy chain, further refines prognostic value by linking ferritin localisation to distinct signalling networks. Advances in bioinformatics, single-cell analyses and in vitro models have deepened our understanding of how ferritin dynamics can serve as prognostic biomarkers, guide risk stratification and inform the development of iron-targeted therapies with global clinical relevance.

Research from Nature Portfolio

In a retrospective analysis of non-metastatic nasopharyngeal carcinoma patients, serum ferritin levels were measured and stratified into tertiles. Individuals with the highest ferritin concentrations exhibited significantly shorter overall survival and progression-free survival compared with those in the lowest tertile. Multivariate models confirmed high serum ferritin as an independent prognostic factor alongside advanced tumour and nodal staging. This study highlights the utility of routine chemiluminescent ferritin assays to refine prognostic modelling and support personalised treatment planning in head and neck cancers.

Ferritin Dynamics in Cancer Prognostics publication trend

The graph below shows the total number of articles in ferritin dynamics in cancer prognostics across all publications each year (not limited to Nature Index journals).

Technical terms

Ferritin: spherical protein complex that stores and releases iron in cells.
FTH1 (Ferritin Heavy Chain): catalytic subunit of ferritin with ferroxidase activity, crucial for converting Fe2+ to Fe3+.
FTL (Ferritin Light Chain): subunit that facilitates iron nucleation and long-term storage within ferritin.
Serum Ferritin (SF): circulating ferritin measured in blood, indicative of body iron stores and inflammatory status.
Ferroptosis: regulated cell death driven by iron-dependent lipid peroxidation.
Tumour Immune Microenvironment (TIME): the network of immune cells, signalling molecules and stroma interacting with a tumour.
Prognostic Biomarker: a measurable indicator that predicts disease outcome independently of specific treatments.

References

1. A comprehensive pan-cancer analysis of prognostic value and potential clinical implications of FTH1 in cancer immunotherapy. Cancer Immunology, Immunotherapy (2024).
2. Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation. Cancers (2023).
3. Iron affects the sphere-forming ability of ovarian cancer cells in non-adherent culture conditions. Frontiers in Cell and Developmental Biology (2023).
4. Serum ferritin predicted prognosis in patients with nasopharyngeal carcinoma. Scientific Reports (2024).